Metabolically Healthy Obesity
Open accessThe DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Abstract
Obesity contributes to reduced life expectancy, impaired quality of life, and disabilities, mainly in those individuals who develop cardiovascular diseases, type 2 diabetes, osteoarthritis, and cancer. However, there is a large variation in the individual risk to developing obesity-associated comorbid diseases that cannot simply be explained by the extent of adiposity. Observations that a proportion of individuals with obesity have a significantly lower risk for cardiometabolic abnormalities led to the concept of metabolically healthy obesity (MHO). Although there is no clear definition, normal glucose and lipid metabolism parameters—in addition to the absence of hypertension—usually serve as criteria to diagnose MHO. Biological mechanisms underlying MHO lower amounts of ectopic fat (visceral and liver), and higher leg fat deposition, expandability of subcutaneous adipose tissue, preserved insulin sensitivity, and beta-cell function as well as better cardiorespiratory fitness compared to unhealthy obesity. Whereas the absence of metabolic abnormalities may reduce the risk of type 2 diabetes and cardiovascular diseases in metabolically healthy individuals compared to unhealthy individuals with obesity, it is still higher in comparison with healthy lean individuals. In addition, MHO seems to be a transient phenotype further justifying therapeutic weight loss attempts—even in this subgroup—which might not benefit from reducing body weight to the same extent as patients with unhealthy obesity. Metabolically healthy obesity represents a model to study mechanisms linking obesity to cardiometabolic complications. Metabolically healthy obesity should not be considered a safe condition, which does not require obesity treatment, but may guide decision-making for a personalized and risk-stratified obesity treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Hyperplasia, referring to an increase in the number of adipocytes, is associated with an increase in subcutaneous fat volume and protective signals, and is associated with MHO (50).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [50]
The cited source says what the claim attributes to it.
In the citing paper
“On the contrary, hypertrophic adipocytes, in which existing adipocytes enlarge, is associated with increased dysfunction and MUHO (50), which contributes to IR and subsequent T2D (52, 53).”
From Metabolic impact of endogenously produced estrogens by adipose tissue in females and males across the lifespan (2025) · cites this paper as [50]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,947
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Abarca-Gómez, L., Abdeen, Z. A., Hamid, Z. A., Abu-Rmeileh, N. M., Acosta-Cazares, B., Acuin, C., Adams, R. J., Aekplakorn, W., Afsana, K., Aguilar-Salinas, C. A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32129-3 · Cited by 7,482
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Obesity: global epidemiology and pathogenesis
Blüher, M. (2019) · Nature Reviews Endocrinology · doi:10.1038/s41574-019-0176-8 · Cited by 5,126 · cited 7×
“8 Endocrine Reviews, June 2020, 41(3):1–16 Blüher Metabolically Healthy Obesity sex hormones may play a role in the transition from MHO to MUO.”
BackgroundInfluentialSelf-citationThe global obesity pandemic: shaped by global drivers and local environments
Swinburn, B. A., Sacks, G., Hall, K. D., McPherson, K., Finegood, D. T., Moodie, M. L., & Gortmaker, S. L. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60813-1 · Cited by 4,888
Cited by
Items 301–400 of 999
Vorobeľová, L., Falbová, D., & Siváková, D. (2021) · Anthropological Review · doi:10.2478/anre-2021-0008 · Cited by 14
Cheng, Q., Yuan, X., Lin, S., Zhao, Y., Wang, H., Zhu, F., Wang, Y., Xu, T., Wu, J., Wang, K., et al. (2022) · Journal of Proteomics · doi:10.1016/j.jprot.2022.104556 · Cited by 11
Seo, D. H., Cho, Y., Seo, S., Ahn, S. H., Hong, S., Ha, K. H., Shim, J., Kim, H. C., Kim, D. J., & Kim, S. H. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11092440 · Cited by 15
Wei, Y., Wang, R., Wang, J., Han, X., Wang, F., Zhang, Z., Xu, Y., Zhang, X., Guo, H., Yang, H., et al. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad047 · Cited by 11
LncRNA Nron deficiency protects mice from diet-induced adiposity and hepatic steatosis
Liu, B., Zhong, Y., Huang, D., Yang, L., Wang, P., Liu, Y., Zhang, F., Li, X., Liang, M., Huang, K., et al. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155609 · Cited by 12
da Fonseca, A. C. P., Assis, I. S. D. S., Salum, K. C. R., Palhinha, L., Abreu, G. D. M., Zembrzuski, V. M., Campos, M., Nogueira-Neto, J. F., Cambraia, A., Souza, M. L. F., et al. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1363417 · Cited by 16
“However, it was reported that ~10 – 30% of subjects with obesity have a lower risk for cardiometabolic abnormalities (Blüher, 2020) — similar to our fi ndings.”
BackgroundZheng, K., Liu, X., Li, Y., Cui, J., & Li, W. (2024) · Scientific Reports · doi:10.1038/s41598-024-63806-1 · Cited by 12
“Excessive fat deposition increases adipokine release and leads to adipocyte hypoxia, allowing for increased cytokines and immune cell recruitment, which may lead to higher levels of systemic inflammation 21,39 .”
BackgroundSu, Y., Li, Y., Ding, R., Zheng, Z.-Y., Wang, J., Fu, Q., Deng, J., & Zhou, H. (2024) · Medicine Advances · doi:10.1002/med4.57 · Cited by 11
Management of male obesity-related secondary hypogonadism: A clinical update
Shenoy, M. T., Mondal, S., Fernandez, C. J., & Pappachan, J. M. (2024) · World Journal of Experimental Medicine · doi:10.5493/wjem.v14.i2.93689 · Cited by 14
Delfan, M., Behzadi, N. J., Juybari, R. A., Daneshyar, S., Saeidi, A., Willems, M. E. T., Hackney, A. C., Laher, I., & Zouhal, H. (2024) · Journal of Functional Foods · doi:10.1016/j.jff.2024.106315 · Cited by 14
“…is a main contributing factor to chronic low-grade inflammation that puts individuals at risk for chronic health problems, including type 2 diabetes (T2DM), metabolic syndrome, cardiovascular disease, hypertension, insulin resistance, fatty liver disease, and dyslipidemia (Blüher, 2020).”
BackgroundChin, C., Han, Y., Han, Y., Toh, D.-F., Bryant, J., Boubertakh, R., & Thu-Thao, L. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1439691 · Cited by 12
“Such inadequacy in re fl ecting true adiposity and the associated cardiometabolic risk has given rise to phenomena such as normal-weight obesity (39, 40) and metabolically healthy obesity (41).”
From NAFLD to MAFLD and MASLD: a tale of alcohol, stigma and metabolic dysfunction
Ciardullo, S., & Perseghin, G. (2024) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2024.39 · Cited by 15
Teymoori, F., Mokhtari, E., Jahromi, M. K., Farhadnejad, H., Mirmiran, P., Vafa, M., & Azizi, F. (2022) · BMC Public Health · doi:10.1186/s12889-022-13401-8 · Cited by 11
Maternal body mass index and placental weight: a role for fetal insulin, maternal insulin and leptin
Kristiansen, O., Roland, M. C. P., Zucknick, M., Reine, T. M., Kolset, S. O., Henriksen, T., Lekva, T., & Michelsen, T. M. (2022) · Journal of Endocrinological Investigation · doi:10.1007/s40618-022-01842-2 · Cited by 13
Huangfu, G., Jaltotage, B., Pang, J., Lan, N. S. R., Abraham, A., Otto, J. H., Ihdayhid, A. R., Rankin, J. M., Chow, B. J. W., Watts, G. F., et al. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155370 · Cited by 12
Netto, A. M., Kashiwagi, N. M., Minanni, C. A., Santos, R. D., & Cesena, F. Y. (2023) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2023.03.020 · Cited by 13
Effectiveness of Bariatric Surgery in Patients with the Metabolically Healthy Obese Phenotype
Genua, I., Tuneu, L., Ramos, A., Stantonyonge, N., Caimari, F., Balagué, C., Fernández–Ananín, S., Sánchez‐Quesada, J. L., Pérez, A., & Miñambres, I. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04967-6 · Cited by 14
Adipocyte Phenotype Flexibility and Lipid Dysregulation
Preston, K. J., Scalia, R. G., & Autieri, M. V. (2022) · Cells · doi:10.3390/cells11050882 · Cited by 13
Lipid-associated macrophages and metabolic inflammatory diseases
Zheng, Y., Tu, D., Dong, C., Zhao, H., & Wang, H. (2026) · Cell Insight · doi:10.1016/j.cellin.2026.100312 · Cited by 14
“In the obese state, the expansion of adipose tissue is not only a change in the number and volume of adipocytes, but also accompanied by the imbalance of lipid droplet (LD) homeostasis and local inflammatory responses (Blüher, 2020).”
Mir, F. A., Mall, R., Ullah, E., Iskandarani, A., Cyprian, F. S., Samra, T. A., Alkasem, M., Abdalhakam, I., Farooq, F., Taheri, S., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04074-x · Cited by 14
Independent association of thigh muscle fat density with vascular events in Korean adults
Choe, H. J., Chang, W., Blüher, M., Heymsfield, S. B., & Lim, S. H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02138-w · Cited by 13
Self-citationEpicardial Adipose Tissue Thickness and Preserved Ejection Fraction Heart Failure
Dhore-Patil, A., Urina‐Jassir, D., Samson, R., Jemtel, T. H. L., & Oparil, S. (2024) · Current Hypertension Reports · doi:10.1007/s11906-024-01302-7 · Cited by 13
Geschlechterspezifische Aspekte kardiovaskulärer Erkrankungen
Baessler, A., Bauer, P., Becker, M., Berrisch-Rahmel, S., Goldmann, B. U., Grünig, E., Hamm, C., Meder, B., Kindermann, I., Ong, P., et al. (2024) · Die Kardiologie · doi:10.1007/s12181-024-00694-9 · Cited by 11
Different associations between body mass index and Alzheimer’s markers depending on metabolic health
Lee, E. H., Yoo, H., Kim, Y. J., Cheon, B. K., Ryu, S., Chang, Y., Yun, J., Jang, H., Kim, J. P., Kim, H. J., et al. (2024) · Alzheimer s Research & Therapy · doi:10.1186/s13195-024-01563-z · Cited by 13
Olshvang, D., Harris, C., Chellappa, R., & Santhanam, P. (2024) · PLoS ONE · doi:10.1371/journal.pone.0309830 · Cited by 14
Lindfors, E. O., Oliveira, T. L. D., Reynolds, C. A., Zhan, Y., Aslan, A. K. D., Jylhävä, J., Sjölander, A., & Karlsson, I. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16004 · Cited by 13
Brogren, E., Andersson, M., Westenius, M., Wittrup, J., & Zimmerman, M. (2024) · BMC Musculoskeletal Disorders · doi:10.1186/s12891-024-08073-x · Cited by 12
Tang, Y., Li, L., & Li, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1499120 · Cited by 12
Deng, J., He, L., Zhang, L., Wang, J., Fu, Q., Ding, R., Lv, Y., Jiang, Y., Xiao, X., & Zhou, H. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01741-5 · Cited by 14
“Individuals with MHO often present lower visceral, higher leg fat deposition, and preserved beta-cell function than persons with metabolically unhealthy obesity (MUO) [14].”
Effects of obesity‐associated plasma markers on adipose stem cell function and epigenetic regulation
Bispo, A. F. S., Simão, J. D. J., Moraes, M., Abel, A. B. M., Plata, V. T. G., Telles, M. M., Santana, A. V., Volpe, P., Armelin‐Correa, L., & Alonso‐Vale, M. I. C. (2025) · Obesity · doi:10.1002/oby.24321 · Cited by 10
Redefining obesity: beyond body mass index
Butler, J., Fioretti, F., & Davies, M. J. (2025) · European Heart Journal · doi:10.1093/eurheartj/ehaf409 · Cited by 12
Obesity phenotypes and atherogenic dyslipidemias
Choe, H. J., Almas, T., Neeland, I. J., Lim, S. K., & Després, J. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70151 · Cited by 18
“26,27 Excess visceral adipose tissue (VAT), which refers to fat stored within the abdominal cavity around organs such as the omentum and mesentery, is particularly atherogenic.”
Covid-19 & Obesity: Beyond Bmi
Nadolsky, K. Z., Hurley, D. L., & Garvey, W. T. (2020) · Endocrine Practice · doi:10.4158/ep-2020-0302 · Cited by 11
Zhang, J., Xu, Q., Lai, F., Chen, N., Lin, M., Liu, Y., Zhang, W., Liu, C., Wang, S., & Li, Z. (2021) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2021-002362 · Cited by 10
Bandres‐Meriz, J., Majali‐Martinez, A., Hoch, D., Morante, M., Glasner, A., van Poppel, M. N. M., Desoyé, G., & Herrera, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910422 · Cited by 10
“jects having normal metabolism [20], we also included metabolic parameters (secondary exposures: glucose, C-peptide, and ISHOMA) to delineate potential metabolic pathways.”
BackgroundMethodInfluentialSolar, I., Ribeiro, F. B., Barbosa, M. G., Freitas, R. G. B. D. O. N., Hanada, A. S., Ramos, C. D. O., Sant’Ana, M. R., Candreva, T., de Almeida-Pititto, B., Tura, A., et al. (2023) · Endocrine · doi:10.1007/s12020-023-03356-0 · Cited by 13
“the metabolic phenotypes of obesity has provided an interesting human model for understanding the underlying mechanisms that promote body fat accumulation and the development of obesity-related changes and cardiometabolic diseases [3].”
BackgroundAssociation between Metabolically Healthy Status and Risk of Gastrointestinal Cancer
Cui, H., Tian, F., Chen, Y., & Ma, X. (2023) · Cancer Research and Treatment · doi:10.4143/crt.2023.539 · Cited by 11
Cruz, K. J. C., de Oliveira, A. R. S., Fontenelle, L. C., Morais, J. B. S., Melo, S. R. D. S., dos Santos, L. R., de Sousa, T. G. V., de Freitas, S. T., Henriques, G. S., Bordin, S. A., et al. (2023) · Biological Trace Element Research · doi:10.1007/s12011-023-03938-z · Cited by 14
Yang, B., Wang, W., Jian, C., Lv, B., He, H., Wang, M., Li, S., & Guo, Y. (2024) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-024-05034-x · Cited by 12
“Due to the difficulty of maintaining a healthy weight, pharmacotherapy is a widely accepted treatment option for improving metabolic health parameters [6].”
Goday, A., Julià, H., de Vargas‐Machuca, A., Pedro‐Botet, J., Benavente, S., Ramón, J. M., Pera, M., Casajoana, A., Villatoro, M., Fontané, L., et al. (2021) · Surgery for Obesity and Related Diseases · doi:10.1016/j.soard.2021.07.021 · Cited by 14
Yu, M., Zhang, S., Wang, L., Wu, J., Li, X., & Yuan, J. (2022) · Nutrients · doi:10.3390/nu14235123 · Cited by 10
Costa, A., van der Stelt, I., Reynés, B., Konieczna, J., Fiol, M., Keijer, J., Palou, A., Romaguera, D., van Schothorst, E. M., & Oliver, P. (2022) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202200503 · Cited by 11
Recent research advances in metabolism, clinical and experimental
Boutari, C., Kokkorakis, M., Stefanakis, K., Valenzuela-Vallejo, L., Axarloglou, E., Volčanšek, Š., Chakhtoura, M., & Mantzoros, C. S. (2023) · Metabolism · doi:10.1016/j.metabol.2023.155722 · Cited by 9
Obesity and diabetes – are they always together?
Shestakova, M. V., Shestakova, E. A., Sklyanik, I. A., & Stafeev, I. (2022) · Terapevticheskii arkhiv · doi:10.26442/00403660.2022.10.201880 · Cited by 17
“Стимулированная секреция инсулина (индекс инсулиногенности, мЕд/ммоль) 29,3 [17,0; 58,1] 14,8 [4,9; 28,4] <0,0005”
Liu, J., Li, L., Xu, D., Li, Y., Chen, T., Liu, Y., Bao, Y., Wang, Y., Yang, L., Li, P., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2367-9 · Cited by 10
“…in humans with similar obesity, those with more fat accumulation in VAT than those with more fat accumulation in SAT are often accompanied by severe metabolic disease, called metabolically unhealthy obese (MUO), in contrast to MHO (Blüher, 2020; Morigny et al., 2021; Vishvanath and Gupta, 2019).”
BackgroundJo, J., Ha, N., Ji, Y., Ra, A., Seo, J. H., Oh, B., Choi, S., Choe, E. K., Lee, W., Son, J. W., et al. (2024) · Briefings in Bioinformatics · doi:10.1093/bib/bbae389 · Cited by 9
“Although the mechanisms of ZNF259 have not been extensively studied, they have been reported to be associated with the risk of CVD, which serves as the main association that distinguishes MHO from MUO (the MHO group is known to have a lower risk of CVD than the MUO group) [33,41,47].”
BackgroundResultDesiderio, A., Pastorino, M., Campitelli, M., Prevenzano, I., Palma, F. D. E. D., Spinelli, R., Parrillo, L., Longo, M., Milone, M., Miele, C., et al. (2024) · The FASEB Journal · doi:10.1096/fj.202401470r · Cited by 10
Jan, Y. J., Chiang, C., Osataphan, S. A., Lawless, A. R., Reynolds, K. L., & Sullivan, R. J. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009769 · Cited by 11
Osataphan, S. A., Awidi, M. A., Jan, Y. J., Gunturu, K. S., Sundararaman, S. K., Viray, H., Frankenberger, E., Mariano, M., O’Loughlin, L., Piper‐Vallillo, A. J., et al. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.108023 · Cited by 10
Lara-Guzmán, O. J., Arango-González, Á. M., Álvarez, R., Escobar, J. S., Muñoz-Durango, K., & Sierra, J. A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031176 · Cited by 15
Kim, M., Lee, J., Lim, D. J., Ishikawa, K. M., Davis, J. W., Lim, E., & Ahn, H. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf214 · Cited by 9
Kobayashi, E., Linden-Santangeli, N. J., Chan, N., Toomey, C. B., Mudaliar, S. R. D., Temprosa, M. G., Edelstein, S. L., Goyal, R., Rangamani, P., Majithia, A. R., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0866 · Cited by 13
Obesity and Chronic Kidney Disease: The Dual Epidemic in Cardiovascular Health
Grant, C. H., & Bell, S. (2025) · European Cardiology Review · doi:10.15420/ecr.2025.33 · Cited by 12
Chen, X., Zhao, X., Fei, H., Zhang, Y., Pang, J., Liu, Z., Wang, W., Qiao, J., & Cuiping, X. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03038-3 · Cited by 14
“Dysregulation of glucose and lipid homeostasis, together with persistent inflammatory activity, fosters insulin resistance (IR) and atherogenic dyslipidemia, leading to sustained hyperglycemic and hyperlipidemic states that aggravate endothelial injury [8–10].”
Cosma, T., Avram, L., Donca, V., Grosu, A. I., Stoicescu, L., Buzdugan, E., Nemeș, A., Bălan, A. M., & Crișan, D. (2025) · Nutrients · doi:10.3390/nu17243940 · Cited by 10
Ren, Z., Cao, X., Li, C., Zhang, J., Li, X., Song, P., Zhu, Y., & Liu, Z. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.922863 · Cited by 10
Zhang, X., Li, G., Shi, C., Tian, Y., Zhang, L., Zhang, H., & Sun, Y. (2023) · Scientific Reports · doi:10.1038/s41598-023-34969-0 · Cited by 12
Putra, I., Daly, M., Sutin, A., Steptoe, A., & Robinson, E. (2023) · Health Psychology · doi:10.1037/hea0001284 · Cited by 7
Fusco, S. A. D., Mocini, E., Gulizia, M. M., Gabrielli, D., Grimaldi, M., Oliva, F. G., & Colivicchi, F. (2024) · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity · doi:10.1007/s40519-023-01630-8 · Cited by 10
“An interesting clarification of this controversy could come from the distinction between metabolically healthy and metabolically unhealthy obesity, probably considering the former as a transitional phenotype towards the latter [154].”
BackgroundPriscilla, L., Yoo, C., Jang, S., Park, S., Lim, G., Kim, T., & Lee, D. Y. (2024) · Bioactive Materials · doi:10.1016/j.bioactmat.2024.01.027 · Cited by 13
“A recent study has demonstrated that when WAT overcomes overnutrition by undergoing adipocyte hyperplasia, which involves an increase in the number of cells, it leads to obese patients exhibiting normal levels of inflammatory markers [9].”
BackgroundMetabolically healthy obesity and health risks - a review of meta-analyses
Čermáková, E., & Forejt, M. (2024) · Central European Journal of Public Health · doi:10.21101/cejph.a7806 · Cited by 9
Masih, D., Tripathi, J. K., Rakhra, G., Vats, A., Verma, S. K., Jha, P. K., Sharma, M., Ashraf, M. Z., & Singh, S. N. (2021) · Genes · doi:10.3390/genes12020290 · Cited by 11
Min, J., Hu, X., Zhang, J., Zeng, T., Wang, Y., Tian, S., Liu, G., Zhong, X., Qiu, K., Peng, M., et al. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s313475 · Cited by 10
Mirzababaei, A., Daneshzad, E., Shiraseb, F., Pourreza, S., Setayesh, L., Clark, C. C. T., Tangestani, H., Abaj, F., Yarizadeh, H., & Mirzaei, K. (2021) · BMC Endocrine Disorders · doi:10.1186/s12902-021-00860-0 · Cited by 9
Bailey, D. P., Stringer, C. A., Maylor, B. D., & Zakrzewski-Fruer, J. K. (2022) · Nutrients · doi:10.3390/nu14030605 · Cited by 11
Long-term impact of the metabolic status on weight loss-induced health benefits
Soll, D., Gawron, J., Pletsch‐Borba, L., Spranger, J., & Mai, K. (2022) · Nutrition & Metabolism · doi:10.1186/s12986-022-00660-w · Cited by 8
“A recent review on this subject also points out that metabolically healthy obesity might represent a transitional state for some patients that might turn into metabolically unhealthy obesity at one point [31].”
BackgroundZhang, Z., Wang, L., Zhan, Y., Xie, C., Xiang, Y., Chen, D., & Wu, Y. (2022) · BMC Cardiovascular Disorders · doi:10.1186/s12872-022-02554-4 · Cited by 9
“Obesity is defined as BMI ≥ 30 kg/m2 [16].”
BackgroundAmadou, C., Heude, B., de Lauzon‐Guillain, B., Lioret, S., Descarpentrie, A., Ribet, C., Zins, M., & Charles, M.-A. A. (2022) · Diabetes & Metabolism · doi:10.1016/j.diabet.2022.101414 · Cited by 10
Dündar, İ., & Akıncı, A. (2023) · Cureus · doi:10.7759/cureus.35935 · Cited by 9
“At the same time, the endocrine, immune, and inflammatory profiles of these obese children are intact [7-11].”
BackgroundLeptin System in Obese Dog Skin: A Pilot Study
Maranesi, M., Loria, A. D., Dall’Aglio, C., Piantedosi, D., Lepri, E., Ciaramella, P., & Mercati, F. (2020) · Animals · doi:10.3390/ani10122338 · Cited by 13
“Moreover, it is noteworthy to underline that only a subset of obese dogs falls within the ORMD, for which hyperlipidemia represents one of the main characters, and in the same way in obese people is known a condition defined as “metabolically healthy obesity” [49].”
BackgroundVitamin D Deficiency and Risk of Metabolic Syndrome in Aging Men
D’Amelio, P. (2021) · The World Journal of Men s Health · doi:10.5534/wjmh.200189 · Cited by 11
Wang, Y., Pan, L., Wan, S., Yihuo, W.-L., Yang, F., Li, Z., Yong, Z., & Shan, G. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1020457 · Cited by 11
“They have normal insulin sensitivity and inflammatory response and are usually free from cardiovascular metabolic risk factors (4).”
BackgroundWang, X., Dong, J.-Y., Du, Z., Jiang, J., Hu, Y., Qin, L., & Hao, Y. (2022) · Nutrients · doi:10.3390/nu14245223 · Cited by 8
Trends and characteristics of the metabolically healthy obese phenotype in an Arab population
Wani, K., Kumar, B., Al‐Daghri, N. M., & Sabico, S. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1371359 · Cited by 9
“Although obesity is often associated with several unfavorable health consequences, some individuals with obesity have a healthy metabolic profile (38, 39).”
BackgroundAssociation between Gut Microbiota and Metabolic Health and Obesity Status in Cats
Yeon, K.-D., Kim, S.-M., & Kim, J.-H. (2024) · Animals · doi:10.3390/ani14172524 · Cited by 10
Wang, X., Wu, Y. H., Wang, Y., Zhou, J., & Liu, T. (2024) · BMC Public Health · doi:10.1186/s12889-024-20254-w · Cited by 8
“However, there is a subset of individuals with overweight/obesity who exhibit favorable blood pressure, glucose, and lipid levels despite excessive fat accumulation, a condition known as “metabolically healthy overweight/obesity (MHO) “ [7, 8].”
BackgroundLu, Y., Ye, S., Gu, Y., Xia, Q., & Hou, L. (2024) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3849 · Cited by 9
“One such subtype is metabolically healthy obese (MHO), which refers to individuals who are obese but still maintain good metabolic health [9].”
The association between white blood cell counts and metabolic health obesity among US adults
Li, Z., Yao, Z., & Liu, Q. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1458764 · Cited by 8
Yuan, Y. E., Haas, A. V., ROSNER, B. A., Williams, G. H., McDonnell, M. E., & Adler, G. K. (2025) · Obesity · doi:10.1002/oby.24218 · Cited by 9
“Over the past decade, there has been growing interest to better characterize and understand the differences between “ metabolically unhealthy ” and “ metabolically healthy ” over-weight/obesity [3 – 7].”
Askeland, A., Rasmussen, R. W., Gjela, M., Frøkjær, J. B., Højlund, K., Mellergaard, M., & Handberg, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-85508-y · Cited by 11
“As such, stratification of obese individuals based on metabolic risk (i.e. with/without NAFLD and MetS) has been proposed to improve clinical management, ultimately to limit obesity and NAFLD progression as well as reducing or reversing the development of liver fibrosis 32 .”
InfluentialAssessment of the Risk of Insulin Resistance in Workers Classified as Metabolically Healthy Obese
Samuelsson, M. G., López, P. J. T., López‐González, Á. A., Paublini, H., Rifá, E. M.-A., & Ramírez‐Manent, J. I. (2025) · Nutrients · doi:10.3390/nu17081345 · Cited by 8
Pather, R., Khathi, A., & Ngubane, P. S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1538627 · Cited by 16
“The metabolically healthy obese subtype is characterized by preserved insulin sensitivity and lowered risk for cardiometabolic complications (33, 34).”
Yang, L., & Jiang, S. (2025) · Precision Chemistry · doi:10.1021/prechem.5c00007 · Cited by 9
Orioli, L., Thissen, J.-P., & Loumaye, A. (2025) · Clinical Nutrition · doi:10.1016/j.clnu.2025.106547 · Cited by 10
Ábel, T., & Csajbókné, É. C. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27031186 · Cited by 12
Greiner, B. H., & Hartwell, M. L. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.07.005 · Cited by 8
Woldu, M. A., Minzi, O., & Engidawork, E. (2022) · JRSM Cardiovascular Disease · doi:10.1177/20480040221114651 · Cited by 11
“MHO is usually diagnosed based on normal glucose and lipid metabolism indicators, as well as the absence of hypertension (HTN), whereas MUH-NW are individuals of normal weight who are at an elevated risk of metabolic illnesses such as DM and HTN.(16,17) Waist circumference (WC) and waist-to-height ratio (WHtR), in add…”
BackgroundInfluentialObesity, leptin and host defence ofStreptococcus pneumoniae: the case for more human research
Hales, C., Burnet, L., Coombs, M. A., Collins, A. M., & Ferreira, D. M. (2022) · European Respiratory Review · doi:10.1183/16000617.0055-2022 · Cited by 8
Noguez-Imm, R., Muñoz, J., Medina, D., Bárcenas, E., Molero-Castillo, G. G., Reyes-Ortega, P., Hughes-Cano, J. A., Gracia-Medrano, L., Miranda‐Anaya, M., Rojas‐Piloni, G., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0278388 · Cited by 9
Taherifard, E., Taherifard, E., Jeddi, M., Ahmadkhani, A., Kelishadi, R., Poustchi, H., Gandomkar, A., Malekzadeh, F., Mohammadi, Z., & Vardanjani, H. M. (2024) · Health Science Reports · doi:10.1002/hsr2.1909 · Cited by 13
CEFALO, C. M. A., Riccio, A., Succurro, E., Marini, M. A., Fiorentino, T. V., Rubino, M., Perticone, M., Sciacqua, A., Andreozzi, F., & Sesti, G. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15646 · Cited by 11
Candi, E., Campanelli, M., Sica, G. S., Schinzari, F., Rovella, V., Daniele, N. D., Melino, J., & Tesauro, M. (2021) · Endocrine and Metabolic Science · doi:10.1016/j.endmts.2020.100077 · Cited by 11
“…uration of type 2 diabetes and better hyperglycemic parameters are he main determinants of diabetes remission and metabolic syndrome eduction ( Blüher, 2020 , Marafini et al., 2015 ). uture Investigations While studying MHO and MUO, studies into genetic traits could bring nsights into…”
BackgroundKeirns, B. H., Hart, S. M., Sciarrillo, C. M., Poindexter, K. L., Clarke, S. L., & Emerson, S. R. (2021) · Obesities · doi:10.3390/obesities1010006 · Cited by 8
“, abnormal fasting glucose, HDL-C, triglycerides, blood pressure), are not treated with glucose-lowering and/or anti-hypertensive medications, and have no history of CVD [5].”
BackgroundZhu, X., Hu, J., Yang, M. G., Guo, H., Ji, D., Li, Y., Wang, W., Xue, C., Wang, N., Zhang, X., et al. (2021) · Gene · doi:10.1016/j.gene.2021.145593 · Cited by 8
Effect of a virtual cardiac rehabilitation program on patients with hypertension: A randomized trial
Leandro, L. A. B., de Araújo, G. C. R., Prado, J. P., de Aquino, T. N., da Silva, J. P., & Galdino, G. (2021) · Fisioterapia em Movimento · doi:10.1590/fm.2021.34126 · Cited by 10
Novel biomarkers of childhood and adolescent obesity
Cardozo, L. L. Y., & Romero, D. G. (2021) · Hypertension Research · doi:10.1038/s41440-021-00651-z · Cited by 9
Integrated microbiome-metabolome-genome axis data of Laiwu and Lulai pigs
Lai, X., Zhang, Z., Zhang, Z., Liu, S., Bai, C., Chen, Z., Qadri, Q. R., Fang, Y., Wang, Z., Pan, Y., et al. (2023) · Scientific Data · doi:10.1038/s41597-023-02191-2 · Cited by 9
Ma, Q., Huang, L., Long, C., & Lin, W. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c03370 · Cited by 7
Metabolic obesity phenotypes and the risk of cancer: a prospective study of the Kailuan cohort
Zheng, X., Wang, Y., Chen, Y., Liu, Y., Liu, C., Lin, S., Xie, H., Ma, X., Wang, Z., Shi, J., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1333488 · Cited by 7
“According the BMI categories (normal-weight, simple overweight, and simple obesity), participants were classi fi ed into six phenotypes: MHNW, metabolically healthy overweight (MHOW), MHO, metabolically unhealthy normal-weight (MUNW), metabolically unhealthy overweight (MUOW), and MUO.”
BackgroundInfluentialOzcariz, E., Guardiola, M., Amigó, N., Valdés, S., Oualla‐Bachiri, W., Rehues, P., Rojo‐Martínez, G., & Ribalta, J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02488-5 · Cited by 9
Metadata
- Authors
- Blüher, M.
- Affiliations
- Helmholtz Munich (DE)
- Corresponding author
- Blüher, Matthias
- ORCID
- Blüher, Matthias
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2020-03-04
- Volume
- 41
- Issue
- 3
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7098708
- OpenAlex
- W3009496837
- Cited by
- 1,090
- References
- 123
- Citations by year
- 2026: 197 · 2025: 222 · 2024: 213 · 2023: 162 · 2022: 155 · 2021: 105 · 2020: 35
- FWCI
- 86.17
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrine Reviews (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion, cc-by)
- PuSH - Publication Server of Helmholtz Zentrum München (submittedVersion)
- Funders
- Deutsche Forschungsgemeinschaft (209933838)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
- Keywords
- metabolically healthy obesity, obesity, cardiometabolic risk, type 2 diabetes, cardiovascular disease, insulin sensitivity, beta-cell function, ectopic fat, visceral fat, liver fat, leg fat, cardiorespiratory fitness, weight loss, obesity treatment, risk stratification
- MeSH terms
- Obesity, Metabolically Benign, Cardiometabolic Risk Factors, Diabetes Mellitus, Type 2, Humans, Insulin Resistance, Obesity, Metabolic Syndrome, Adiposity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.